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Prostate cancer is a highly heterogeneous disease and one of the leading causes of mortali-
ty in developed countries. Specific prognostic and predictive markers for prostate cancer
patients are still lacking. A causal relationship between androgens and the development of
prostate cancer is generally considered biologically plausible, but androgens are not the
sole effector in the complexity of prostate carcinogenesis. The aim of this study was to eval-
uate the prognostic significance of progesterone receptor in tumor tissue of T1-3N0 prostate
cancer patients undergoing prostatectomy.
Methods
Tissue microarrays from 535 patients with prostate cancer were constructed. Duplicate
cores of tumor cells and tumor stromal tissue from each resected specimen were extracted.
Immunohistochemistry was used to evaluate the in-situ expression of
progesterone receptor.
Results
In univariate analyses, high tumor cell density (p = 0.006) and high tumor stromal cell densi-
ty level (p = 0.045) of progesterone receptor were both significantly associated with tumor
progression and clinical failure. In multivariate analysis, progesterone receptor expression
in tumor cells was an independent negative prognostic factor for clinical failure (HR: 2.5,
95% CI: 1.2–5.2, p = 0.012).
Conclusion
High progesterone receptor density in tumor cells of the prostate cancer tumor is an inde-
pendent negative prognostic factor for clinical failure.
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Introduction
Prostate cancer (PCa) is one of the leading causes of death amongst men in the western world
[1]. The majority of PCa occurs as an indolent form that is unlikely to invade beyond the local
tissue environment. A subgroup of PCas, however, displays aggressiveness and metastatic
properties. Such cancers result in a rapid disease progression and reduced disease specific sur-
vival [2]. Consequently, the clinical course of PCa is highly individual and difficult to predict
from the start.
In lack of specific molecular markers as diagnostic and prognostic tools, the detection of
PCa and its treatment strategy is still mainly based on the prostate-specific antigen (PSA)
value, Gleason score of tumor biopsies and primary tumor (pT)-staging [3]. PSA cannot sepa-
rate between the different PCa progression patterns. Accordingly, many of the detected PCa
cases represent clinically indolent tumors which untreated will remain stable for years [2].
Hence, PSA screening constitutes a risk for overdiagnosis and overtreatment which is associat-
ed with a negative impact on quality of life and extensive financial costs [4,5]. The identifica-
tion of new, improved prognostic and diagnostic biomarkers for PCa is therefore
greatly needed.
Sex steroid hormones, such as androgens, estrogens and progesterone, are potent effectors
involved in proliferation, differentiation as well as cellular development, and known contribu-
tors to the development of different cancers [6]. The metabolic functions of the prostate is
under the regulatory control of such sex steroid hormones [7]. A causal relationship between
androgens and the development of PCa is, in general, considered biologically plausible [8].
This indicates a crucial role for the androgen receptor in the prostate carcinogenesis and endo-
crine treatment failure. However, there is mounting evidence that the androgen receptor is not
the only effective endocrine receptor in this complex process. Research suggesting the involve-
ment of both the glucocorticoid-, estrogen- and progesterone receptors in this process have
been published [9–13].
Progesterone is a 21-carbon hormone synthesized from steroid precursors in various parts
of the body, including the testes, adrenal gland, placenta and the glia cells of the brain, in addi-
tion to the ovaries [14]. The progesterone receptor (PGR) exists in two isoforms, PGR-A and
PGR-B, and both are transcribed from the same gene. It belongs to the same receptor family as
the androgen- and oestrogen receptors, which are expressed in both stromal and tumor cells of
the PCa tissue [11,13,15–18]. Currently, there is a general agreement of PGR presence in the
stromal cells of PCa [10,17,19–23]. Results regarding PGR’s presence in tumor cells, however,
are conflicting [9,10,17,19–25]. Thus, the importance of PGR in the human prostate and in
prostate carcinogenesis has never been adequately explained. As a consequence we sought to
evaluate the expression of PGR in both tumor cells derived from epithelia (TE) and tumor stro-
mal cells (TS) in malignant prostatectomy specimens and found the PGR density level in both
TE and TS to be associated with PCa progression.
Materials and Methods
Patients, clinical- and histopathological data
671 patients who underwent radical prostatectomies as initial treatment for adenocarcinoma
from 1995 to 2005 were retrospectively identified from the Departments of Pathology at the
University Hospital of Northern Norway (n = 267), the Nordland Hospital (n = 63) and the
St. Olavs Hospital (n = 341). Of these, a total of 136 patients were excluded, due to (i) radio-
therapy to the pelvic region prior to surgery (n = 1), (ii) other malignancies within 5 years
prior to the PCa diagnosis (n = 4), (iii) inadequate paraffin-embedded tissue blocks (n = 130),
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and (iiii) lack of clinical follow-up data (n = 1). None of the patients had received hormonal
therapy prior to or at the time of the prostatectomy. Thus 535 patients with complete follow-
up data were included in this study. Median follow-up time was 89 (range 6–188) months at
the last patient update in November 2012. Complete demographic and clinical data were ob-
tained from medical records. All tissue analyzed and added to the study was processed in a
comparable manner, the tumors were graded according to the modified Gleason grading sys-
tem [26,27], and staged according to the World Health Organization guidelines [28]. All pri-
mary cancers were histologically reviewed by two pathologists (ER and LTB), and all
demographic, clinical and histopathological data (Table 1) were recorded in an SPSS data file,
in which patients were de-identified. The Regional Committee for Medical and Health Re-
search Ethics (2009/1393), the Data Protection Official for Research (NSD), and the National
Data Inspection Board approved this study. All patients were anonymized with each trial num-
ber. These numbers were initially linked to identity for only one purpose prior; to collect clini-
cal information. The Norwegian Social Science Data Service and the University Hospital’s Data
Protection Office accepted this solution (2009/1393). Written consent from the patients was
considered, but as this was a retrospective study where most of the material was more than 10
years old and most of the patients deceased, it was considered not needed. All data was
analysed anonymously.
Microarray construction
Tissue Microarray (TMA) construction was chosen for high-throughput molecular pathology
analyses. For each tissue block, a pathologist (ER) identified and marked two representative
areas of epithelial tumor tissue and two for tumor stromal tissue on the corresponding haema-
toxylin and eosin slides. One area with normal epithelial cells, and one with normal stromal tis-
sue were also carefully marked. From each of these areas, cores were sampled from each donor
block in order to construct TMA blocks. Prostate cores from 20 patients without any history of
malignancy were used as controls.
The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments, Silver
Springs, MD, USA). We used a 0.6 mm diameter needle to harvest cores from the marked tis-
sue areas from each paraffin-embedded tissue blocks. The core samples were inserted into an
empty recipient paraffin block in a precise array pattern. To include all core samples, twelve tis-
sue array blocks were constructed. Multiple 4 μm sections were cut with a Micron microtome
(HM355S), affixed to glass slides, and sealed with paraffin. The detailed methodology has been
reported previously [29].
Immunohistochemistry (IHC)
For immunohistochemical staining, the Ventana Benchmark XT automated staining system
(Ventana Medical Systems, Tucson, AZ) and Ventana reagents were used. TMA slides were
deparaffinised with xylene and rehydrated in decreasing concentrations of ethanol. Endoge-
nous peroxidase was blocked using the Ventana endogenous peroxidase blocking kit after a
rinse with distilled water. For antigen retrieval, slides were heated with cell conditioning solu-
tion (CC1, Ventana), standard, according to the manufacturer’s instructions. The following an-
tibody from Ventana Medical (Tucson, Arizona, USA) was used in this study: CONFIRM anti-
progesterone receptor (clone 1E2, catalogue # 790–4296) rabbit monoclonal primary antibody,
directed against both A and B isoforms of the human progesterone receptor. The antibody was
prediluted by the manufacturer. The applied antibody is produced for routine diagnostic IHC
and has received FDA approval (510k) for IVD (in vitro diagnostic) use. The PGR antibody is
currently applied in routine practice in assessment of PGR status in breast cancer. In order to
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Table 1. Patient characteristics and clinicopathological variables as predictors for BF, CF and PCD in PCa patients (n = 535) (univariate
analyses; log rank test), significant p-values in bold (threshold p  0.05).
Characteristic Patients (n) Patients (%) BF (170 events) CF (36 events) PCD (15 events)
5-yearEFS (%) p 10-year EFS (%) p 10-year EFS (%) p
Age 0.55 0.085 0.600
 65 years 357 67 76 92 97
> 65 years 178 33 70 88 96
pT-Stage <0.001 <0.001 0.027
pT2 374 70 83 96 98
pT3a 114 21 60 86 98
pT3b 47 9 43 73 89
pN-stage <0.001 <0.001 <0.001
NX 264 49 79 95 98
N0 268 50 71 89 97
N1 3 1 0 33 67
Preop PSA <0.001 0.085 0.061
PSA < 10 308 58 80 93 99
PSA > 10 221 41 67 88 95
Missing 6 1 - - -
Gleason <0.001 <0.001 0.001
3+3 183 34 83 98 99
3+4 220 41 76 94 98
4+3 80 15 69 84 95
 4+4 52 10 45 71 89
Tumor size <0.001 0.019 0.098
0–20 mm 250 47 82 94 99
> 20 mm 285 53 67 88 96
PNI <0.001 <0.001 0.002
No 401 75 79 95 98
Yes 134 25 60 81 93
PSM 0.041 0.038 0.697
No 249 47 81 94 97
Yes 286 53 69 89 97
Non-apical PSM <0.001 <0.001 0.029
No 381 71 81 95 98
Yes 154 29 57 81 94
Apical PSM 0.040 0.484 0.313
No 325 61 73 90 96
Yes 210 39 77 92 98
LVI <0.001 <0.001 0.009
No 492 92 77 93 98
Yes 43 8 46 71 87
Surgical proc. 0.230 0.414 0.581
Retropubic 435 81 76 90 97
Perineal 100 19 67 95 98
Abbreviations: BF = biochemical failure; CF = clinical failure; PCD = prostate cancer death; PCa = prostate cancer; EFS = event free survival in months;
LVI = lymphovascular infiltration; NR = not reached; PNI = Perineural infiltration; Preop = preoperative; PSA = Prostate specific antigen; PSM = Positive
surgical margin; Surgical proc = surgical procedure
doi:10.1371/journal.pone.0116691.t001
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validate specificity of the primary antibody against PGR, lysates of HEK 293 cells with either
transiently overexpressed PGR or an empty vector were used. Further details regarding anti-
body validation can be found in the supporting information files (S1 Text, S2 Text, S1 Fig.).
UltraView Universal DAB was used as detection kit. Finally, TMA slides were counterstained
with haematoxylin to visualise the nuclei.
Scoring of IHC
The ARIOL imaging system (Applied Imaging Corp., San Jose, CA, USA) was used to scan and
digitalise the IHC stained TMA slides. The slides were loaded in the SL 50 automated slide
loader and scanned at a low resolution (1.25x) and high resolution (20x) using an Olympus
BX61 microscope with an automated platform (Prior Scientific, Cambridge, UK). Images of
the cores were uploaded into the Ariol Software. All samples were de-identified and scored
manually by two pathologists (ER and SAS) independently of each other and both were blinded
to any pathological or clinical information. In case of disagreement, the slides were re-exam-
ined and the observers reached a consensus. Representative viable tissue sections were scored
semi-quantitatively and the degree of nuclear PRG expression by IHC was graded according to
both dominant staining intensity and density in both TE and TS. Both intensity and density
was given a score between 0–3. Intensity was scored as follows: 0 = negative, 1 = weak, 2 =
moderate, 3 = strong. Density was scored according to the percentage of positive cells in the ex-
amined compartment using the following system: 0 = 0%, 1 = 5%, 2 = 5–50%, 3 => 50%.
For each case, mean scores were calculated. The mean scoring values were then connected to
patient’s clinical and histopathological information. The scoring values were then dichoto-
mised as high and low intensity or density of stained cells (Fig. 1) using optimal cut off values.
In both TE and TS, cut off was defined as the density level × 4th quartile. A high score was de-
fined as density level 0.75 in TE, and 1.75 in TS.
Statistical methods
All statistical analyses were performed using the statistical package IBM SPSS, version 21
(SPSS Inc., Chicago, IL, USA). The IHC scoring values from each pathologist were compared
for inter-observer reliability by use of a two-way random effect model with absolute agree-
ment definition. A Wilcoxon signed rank test was used to assess if there was statistically sig-
nificant differences in PGR intensity and density between the different compartments of the
PCa specimens. We employed the Spearman correlation coefficient to examine the association
between PGR expression and clinopathological variables. The Kaplan-Meier method was
used for the univariate survival analysis, and log-rank test to assess the statistical significance
between the survival curves of the model. Univariate Kaplan Meier curves were constructed
for the following the end-points: 1) Biochemical failure (BF), 2) Clinical failure (CF) and 3)
PCa death (PCD). BF was determined as a PSA recurrence 0.4 ng/ml in a minimum of two
different blood samples postoperatively [30]. CF was defined as verified local symptomatic
progression beyond cure and/or findings of metastasis to bone, visceral organs or lymph
nodes by CT, MR, bone scan or ultrasonography. PCD was defined as death caused by pro-
gressive and disseminated castration-resistant PCa uncontrollable by therapy. All
significant variables from the univariate analysis were entered in the multivariate analysis
using a backward stepwise Cox regression model with a probability for stepwise entry
removal at 0.05 and 0.1, respectively. We considered a p-value< 0.05 as statistically signifi-
cant for all analyses.
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Results
Patient characteristics
The radical prostatectomy was retropubic in 435 cases and perineal in 100 cases. Patients’ age
at surgery ranged from 47 to 76 years with a median age of 62 years. Further particulars regard-
ing the cohort are previously published [31]. An overview of the demographic, clinical and his-
topathological characteristics is presented in Table 1. Combined Gleason score ranged from 6
to10 and tumor stage from T2a to T3b. At the last follow-up 170 (32%) experienced BF, 36
(7%) experienced CF and 15 (3%) had died due to PCa.
Progesterone expression and correlation with clinicopathological
variables
There was a good scoring agreement between the two investigating pathologists. The intra-
class correlation coefficient (reliability coefficient, r) for the PGR marker was 0.78 (p< 0.001).
PGR was expressed in the nucleus of both normal cells and in TE and TS (Fig. 1). High PGR
density in TE ( 0.75) was found in 109 (20%) of the 535 patients whereas, a high PGR density
Fig 1. High and low progesterone receptor (PGR) protein density levels in human prostate cancer
(PCa) tissue sections. Immunohistochemistry microscopic pictures of tissue micro array representing
different expression of PGR staining in PCa sections A-B. (A)High density of PGR in tumor cells (TE),
including magnification. (B) Low density of PGR in TE, including magnification. Original magnification x100
and x400.
doi:10.1371/journal.pone.0116691.g001
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(x 1.75) in TS was found in 120 (23%) of the patients. There was no significant difference in
PGR density level in control epithelia compared to TE (p = 0.429), although the average density
score was 0.37 in control epithelia and 0.52 in TE. In addition, 61.9% of the controls did not ex-
press PGR, while only 28.3% of TE were without PGR expression. However, there was a signifi-
cantly higher PGR density level in TS compared to control stroma (p< 0.001). Further, a
significantly higher expression intensity and density level of PGR was found in TS when com-
pared to TE (both p< 0.001).
High density levels of PGR in TE were correlated with a positive apical margin (p = 0.025)
and perineural infiltration (PNI) (p< 0.01). No correlations to other clinopathological vari-
ables were identified.
Univariate analysis
Associations between the density level of PGR and CFFS (clinical failure free survival) are pre-
sented in Table 2 and Fig. 2. The following clinopathological variables were all significant prog-
nostic factors for CF: pT-stage (p< 0.001), pN-stage (p< 0.001), Gleason grade (p< 0.001),
tumor size (p = 0.019), perineural infiltration (p = 0.001), positive surgical margin (p = 0.038),
non-apical surgical margin (p< 0.001) and lymphovascular infiltration (p< 0.001) (Table 1).
Increasing PGR density levels in both TE (p = 0.006) and TS (p = 0.045) were significantly
associated with CF (Fig. 2, panel A and B). When merging PGR density levels in TE and TS, pa-
tients with high (high/high) PGR density levels had significantly reduced CFFS (p = 0.019)
compared to those with low density levels (low/high, high/low and low/low) (Fig. 2, panel C).
Ten year CFFS were 76.8% vs. 91.6% respectively for patients with high (high/high) density lev-
els vs. low (low/high, high/low and low/low) (Table 2).
High PGR levels in TE showed a similar tendency for increased BF, but this was not statisti-
cally significant (p = 0.144). For TS or TS and TE combined, there were no associations with
BF or PCD.
Table 2. Expression of PGR in TE and TS as predictor for CFFS in PCa patients (n = 535), (univariate analysis; log rank test), significant p-
values in bold (threshold p  0.05).
Marker expression Patients (n) Patients (%) 5-year CFFS (%) 10-year CFFS (%) p
PGR
Density TE 0.006
Low 346 65 97 94
High 109 20 92 82
Missing 80 15
Density TS 0.045
Low 362 68 97 92
High 120 22 96 84
Missing 53 10
Density TE + TS 0.019
Low 416 78 96 92
High 39 7 92 77
Missing 80 15
Abbreviations: PGR = progesterone receptor; CFFS = clinical failure free survival; PCa = prostate cancer; TE = tumor epithelial cells; TS = tumor
stromal cells
doi:10.1371/journal.pone.0116691.t002
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A high density level of PGR in TE was significantly associated with CF in the subgroup
of patients with Gleason score 7 (p = 0.002, Fig. 2, panel D) compared to the subgroup of
patients with Gleason score 6 (p = 0.914). Ten year CFFS for patients with high PGR density
levels were 72.2% vs. 97.2% respectively for patients with Gleason score 7 vs. Gleason
score 6.
Fig 2. High progesterone receptor (PGR) density level is associated with reduced clinical failure free survival (CFFS). Kaplan-Meier curves
displaying proportion of prostate caner patients (n = 535) with CFFS according to high and low density level of progesterone receptor (PGR) in different cell
types A-D. (A) Tumor stromal cells (TS), (B) tumor cells (TE), (C) TE and TS combined and (D) TE in patients with a high Gleason score ( 7). A high PGR
density level is significantly associated with a reduction in CFFS. In both TE and TS, cut off was defined as the density level × 4th quartile. A high score was
defined as density level 0.75 in TE, and 1.75 in TS. Log-rank tests were used to assess the statistical significance between the survival curves of the
model. Median follow-up time was 89 (range 6–188) months. A p-value< 0.05 was considered statistically significant.
doi:10.1371/journal.pone.0116691.g002
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Multivariate analysis
In the multivariate analysis (Table 3), high expression of PGR in TE was an independent pre-
dictor for CF (HR: 2.5, 95% CI: 1.2–5.2, p = 0.012) in addition to Gleason grade (p = 0.001) and
non-apical surgical margin (p = 0.006). PGR expression in TS tended to, but did not reach sta-
tistical significance (HR: 2.1, CI: 1.0–4.3, p = 0.060). No independent prognostic factors were
found for BF and PCD.
Discussion
To our knowledge, this is the first large-scale study investigating the prognostic role of PGR in
TE and TS in PCa. In univariate analysis, a high density level of PGR in both TE and TS was as-
sociated with CF. High density level of PGR in the TE was an independent prognostic factor
for CF.
A first step to understand PGR action in PCa is to define receptor expression in prostate tis-
sue. Previous publications on PGR expression in PCa, especially those using IHC, have pre-
sented contradicting results and only a few reports have addressed PGR’s role in prostate
carcinogenesis. Our large-sized study demonstrates a wide distribution of PGR in stromal and
epithelial cells of both benign and malignant prostate tissue. Currently, there seems to be a gen-
eral agreement of PGR presence in the stromal cells of PCa [10,17,19–23]. In line with our find-
ings, several have also reported a high PGR expression in TE of PCa [9,10,23,25]. In contrast,
others have demonstrated a total lack of PGR expression in TE [17,19,20,22]. Even experimen-
tal studies using cell lines have reported conflicting results [17,24,25,32]. Such discrepancy may
be explained by several factors. This includes use of different antibodies, tissue processing, anti-
gen retrieval methods, number of tissue samples and different scoring systems, and may reflect
Table 3. Cox regression analysis (backwards stepwise model) summarizing significant independent
prognostic factors for CF in PCa patients (n = 535), significant p-values in bold (threshold p  0.05).
Factor CF
HR CI 95% p
Gleason 0.001
3+3 1.00
3+4 2.20 0.67–7.17 0.192
4+3 3.84 1.12–13.15 0.032










Abbreviations: PCa = prostate cancer; CF = clinical failure; PGR = progesterone receptor; TE = tumor
epithelial cells; PNI = perineural infiltration; PSM = positive surgical margin
doi:10.1371/journal.pone.0116691.t003
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a lack of methodological standardization. The monoclonal antibody 1E2 used in our study has
been optimized for clinical use and is used in routine practice in assessment of PGR status in
breast cancer. This is also the case for the NCL-PGR1A6 antibody applied in the articles by
Bonkhoff et al. [10] and Hiramatsu et al. [23], which confirms the presence of PGR in TE. Sev-
eral of the IHC studies contradicting the present study’s finding were performed prior to the
development of new methods increasing methodological accuracy [17,19,20]. Such methods
include the use of new, highly specific monoclonal antibodies against PGR, the microwave irra-
diation method and the time efficient tissue processing method TMA [33], which has been re-
ported as a valuable tool for evaluation of patient material and a good substitute for whole
section analysis [34].
Yu et al. recently investigated the location and role of both PGR isoforms in PCa and report
findings contradictory to ours. This may be explained by their investigation of PGR which they
found to be expressed solely in a subset of stromal cells of the 27 radical prostatectomy speci-
mens [22]. This is in contrast to our work were the expression of PGR in both TE and TS was
clearly detected. In our cohort 129 (28.3%) patients had no PGR expression in TE, in contrast
to only 8 patients (1.7%) with negative PGR staining in TS. However, those with a high density
level of PGR in TE was significantly associated with CF. The difference in cohort size could po-
tentially explain some of the discrepancy between the findings. In addition, both the chosen an-
tibody and tissue processing methods differ.
In another study using cell proliferation assay, Yu et al. found PGR to be negatively regulat-
ing stromal cell proliferation in vitro [32]. In our work univariate analysis demonstrated a high
PGR expression in TS to be associated with clinical failure in PCa patients. So far we have not
yet demonstrated the mechanism underlying this association.
Steroid hormones regulate the cell’s progression through cell cycle by binding to their re-
spective receptors. These receptors are signal transduction molecules and can regulate the pro-
liferation in two different ways, genomic or non-genomic actions in complex signalling
networks [6]. Several non-genomic proliferative actions of progesterone have been proposed in
tumor cells of other organs, including breast [35–37], astrocytoma [38] and osteosarcoma [39]
cell lines. However, such results are contradicted by suggestions of anti-proliferative actions of
progesterone in endometrial cancer [40]. This could indicate that the actions of progesterone
are tissue specific. We found that high PGR density level in TE was associated with CF in pa-
tients with Gleason score 7, suggesting an up-regulation of the PGR in progressing PCa.
This is in consistence with previous publications. Bonkhoff et al. have suggested progressive
emergence of PGR during PCa progression and metastasis [10]. Supporting these findings,
Latil and co-workers found a decreased PGR expression in clinically localized tumors and in-
creased PGR expression in hormone-refractory tumors, when compared with normal prostate
tissue [9].
In several experimental studies by Check et al., mice with PCa were treated with a PGR an-
tagonist, mifepristone, and compared with controls. They found a higher mortality in those
not treated. Moreover, there were less PCa complications in the treated group [41,42]. Similar
findings of anti-progesterone activity of mifepristone in both androgen sensitive and non-sen-
sitive PCa cell lines in vitro and in vivo, have been reported [43,44]. Our findings provide fur-
ther support to these findings, indicating that PGR plays a role in the pathogenesis of PCa.
To investigate whether aberrant PGR activity is a mechanism of castrate resistant prostate can-
cer development, a phase I/II clinical trial has just been initiated to test the effect of the anti-
progestin, onapristone, in patients with this condition (http://clinicaltrials.gov/show/
NCT02049190).
The mechanism behind the PGR up-regulation in PCa has not yet been elucidated. In this
study, Ki67 and PGR in TE were correlated with CF (S3 Text), indicating an association
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between PGR and proliferative activity. Arora et. al. [12] have reported that up-regulation of
the glucocorticoid receptor re-activates the expression of a subset of androgen receptor-regu-
lated genes and thereby induces castrate resistant PCa. The PGR is, like the glucocorticoid re-
ceptor, similar to androgen receptor with 88% sequence homology in the ligand-binding
domain [45]. In line with this finding, progesterone induced expression of androgen receptor-
regulated genes could be a potential mechanism contributing to the development of castrate re-
sistant PCa. However, further research investigating this is warranted for such a hypothesis to
be confirmed.
A possibility of different roles by the two PGR isoforms in normal prostate tissue and PCa,
as is suggested for the estrogen receptors [13], must also be taken into account. We now know
that crosstalk between TE and TS is essential for the development of PCa. In a study by Mem-
arzadeh et al., cancer-associated fibroblast growth factors caused an up-regulation of epithelial
androgen receptor [46]. This could indicate that epithelial-stromal crosstalk is the mechanism
behind induction of PGR expression in TE and it is thereby promoting PCa progression. How-
ever, up-regulation of PGR may not be the direct mechanism behind increased proliferation,
but rather a consequence of other underlying processes. Thus, the respective role of epithelial
versus stromal PGR in prostate carcinogenesis and a potential individual role of the PGR iso-
forms remain to be determined.
Conclusion
Herein, we found that a high density level of PGR in TE is an independent prognostic factor
for progression to CF in PCa. Further, high PGR density levels are significant for progression
to CF in patients with Gleason score 7. Progesterone/PGR may for these reasons be useful
as a prognostic tool, but also as a target for novel treatment strategies in PCa. Further
functional studies investigating PGR’s role in both epithelial and stromal compartments
of PCa are still needed to conclude how to best apply this knowledge in PCa diagnosis
and treatment.
Supporting Information
S1 Dataset. SPSS PCa and PGR dataset.
(SAV)
S2 Dataset. SPSS PCa and Ki67 dataset.
(SAV)
S1 Fig. Lysates of HEK 293 cells with either an empty vector (A) or a PGR overexpression
construct (B) were ran on a SDS-PAGE gel and transferred onto a nitrocellulose mem-
brane. The membrane was first probed with the Ventana anti-PGR antibody (upper panel),
and then with the anti-actin antibody to control for loading (lower panel).
(TIFF)
S1 Text. Antibody specificity validation.
(DOCX)
S2 Text. Ventana product catalogue, CONFIRM anti-Progesterone Receptor (PR) (1E2)
Rabbit Monoclonal Primary Antibody.
(PDF)
S3 Text. Ki67 immunostaining.
(DOCX)
Progesterone Receptor and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0116691 February 27, 2015 11 / 14
Acknowledgments
We wish to thank Magnus Persson, (Department of Clinical Pathology, University Hospital of
Northern Norway), and Mona Pedersen (UiT The Arctic University of Norway) for their very
careful laboratory work.
Author Contributions
Conceived and designed the experiments: TG SA SAS LT-B RMB ER. Performed the experi-
ments: TG SAS SA YK RMB ER. Analyzed the data: TG SA KS TD LT-B RMB ER. Contributed
reagents/materials/analysis tools: TG SA CMJ YK TD LT-B RMB ER. Wrote the paper: TG SA
SAS KS TD LT-B RMB ER.
References
1. IARC IA for R on CWHO (2012) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Preva-
lenceWorldwide in 2012. GLOBOCAN. Available: http://globocan.iarc.fr/Pages/fact_sheets_cancer.
aspx?
2. Klotz L (2013) Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes
20. Available: http://journals.lww.com/co-endocrinology/Fulltext/2013/06000/Prostate_cancer_
overdiagnosis_and_overtreatment.8.aspx.
3. Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, et al. (2014) Androgen receptor antag-
onists for prostate cancer therapy. Endocrine-Related Cancer. Available: http://erc.endocrinology-
journals.org/content/early/2014/03/17/ERC-13-0545.abstract.
4. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, et al. (2003) Lead times and overde-
tection due to prostate-specific antigen screening: estimates from the European Randomized Study of
Screening for Prostate Cancer..
5. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, et al. (2001) Health-related
quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically
diagnosed localized prostate cancer. J Clin Oncol 19: 1619–1628. PMID: 11250990
6. Migliaccio A, Castoria G, Auricchio F (2007) Src-dependent signalling pathway regulation by sex-ste-
roid hormones: Therapeutic implications. Int J Biochem Cell Biol 39: 1343–1348. doi: 10.1016/j.biocel.
2006.12.009 PMID: 17329144
7. Morriss-Kay G (1991) Langman’s Medical Embryology. J Anat 175: 273–274. doi: 10.1097/00006534-
198801000-00024
8. Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18: 52–74.
Available: http://www.ncbi.nlm.nih.gov/pubmed/10617897. PMID: 10617897
9. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, et al. (2001) Evaluation of androgen, estrogen (ER
alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time
quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919–1926.
PMID: 11280747
10. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (2001) Progesterone receptor expression in human
prostate cancer: correlation with tumor progression. Prostate 48: 285–291. Available: http://www.ncbi.
nlm.nih.gov/pubmed/11536308. PMID: 11536308
11. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, et al. (2001) A role for estrogen receptor beta in
the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98: 6330–6335. doi: 10.4048/
jbc.2011.14.1.20 PMID: 11371645
12. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. (2013) Glucocorticoid Receptor Con-
fers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell 155: 1309–1322.
Available: http://www.sciencedirect.com/science/article/pii/S0092867413014256. doi: 10.1016/j.cell.
2013.11.012 PMID: 24315100
13. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, et al. (2001) Frequent loss of estrogen recep-
tor-beta expression in prostate cancer. Cancer Res 61: 5331–5335. PMID: 11454669
14. Aufrère MB, Benson H (1976) Progesterone: An overview and recent advances. J Pharm Sci 65: 783–
800. Available: http://dx.doi.org/10.1002/jps.2600650602. PMID: 945344
15. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, et al. (1992) Nuclear localization of androgen
receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147:
798–803. PMID: 1371552
Progesterone Receptor and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0116691 February 27, 2015 12 / 14
16. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, et al. (1994)
Androgen receptor status in localized and locally progressive hormone refractory human prostate can-
cer. Am J Pathol 144: 735–746. PMID: 7512791
17. Brolin J, Skoog L, Ekman P (1992) Immunohistochemistry and biochemistry in detection of androgen,
progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20:
281–295. PMID: 1376911
18. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, et al. (2001) Comparative studies of the estrogen re-
ceptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in
primary and metastatic carcinoma. Am J Pathol 159: 79–92. PMID: 11438457
19. Wernert N, Gerdes J, Loy V, Seitz G, Scherr O, et al. (1988) Investigations of the estrogen (ER-ICA-
test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical
basis. Virchows Arch A Pathol Anat Histopathol 412: 387–391. doi: 10.1007/BF00750267 PMID:
3125679
20. Mobbs BG, Liu Y (1990) Immunohistochemical localization of progesterone receptor in benign and ma-
lignant human prostate. Prostate 16: 245–251. PMID: 1691842
21. Luetjens CM, Didolkar A, Kliesch S, PaulusW, Jeibmann A, et al. (2006) Tissue expression of the nu-
clear progesterone receptor in male non-human primates and men. J Endocrinol 189: 529–539. Avail-
able: http://joe.endocrinology-journals.org/content/189/3/529.abstract. PMID: 16731784
22. Yu Y, Liu L, Xie N, Xue H, Fazli L, et al. (2013) Expression and function of the progesterone receptor in
human prostate stroma provide novel insights to cell proliferation control. J Clin Endocrinol Metab 98:
2887–2896. Available: http://www.ncbi.nlm.nih.gov/pubmed/23666965. doi: 10.1210/jc.2012-4000
PMID: 23666965
23. Hiramatsu M, Maehara I, Orikasa S, Sasano H (1996) Immunolocalization of oestrogen and progester-
one receptors in prostatic hyperplasia and carcinoma. Histopathology 28: 163–168. PMID: 8834526
24. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, et al. (1997) Metastatic lesions from pros-
tate cancer do not express oestrogen and progesterone receptors. J Pathol 182: 356–361. doi: 10.
1002/(SICI)1096-9896(199707)182:3<356::AID-PATH863>3.0.CO;2-U PMID: 9349240
25. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, et al. (1995) Growth of LNCaP human
prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136: 2309–2319.
PMID: 7536668
26. Helpap B, Egevad L (2009) Modified Gleason grading. An updated review. Histol Histopathol 24:
661–666. Available: http://europepmc.org/abstract/MED/19283673. PMID: 19283673
27. Epstein J (2010) An update of the Gleason grading system. J Urol 183: 433–440. Available: http://
www.sciencedirect.com/science/article/pii/S0022534709027049. doi: 10.1016/j.juro.2009.10.046
PMID: 20006878
28. Chan T (2005) World Health Organization classification of tumours: Pathology & genetics of tumours of
the urinary system and male genital organs. Available: http://scholar.google.com/scholar?hl =
en&btnG=Search&q = intitle:World+Health+Organization+Classification+of+Tumours.+Pathology
+and+Genetics+of+Tumours+of+the+Urinary+System+and+Male+Genital+Organs.#0.
29. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, et al. (2002) High-throughput tissue microar-
ray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-
small-cell lung cancer. J Clin Oncol 20: 2417–2428. doi: 10.1200/JCO.2002.08.159 PMID: 12011119
30. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, et al. (2006) Defining Biochemical Re-
currence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition. J
Clin Oncol 24: 3973–3978. Available: http://jco.ascopubs.org/content/24/24/3973.abstract. PMID:
16921049
31. Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, et al. (2014) Disease-specific outcomes
of Radical Prostatectomies in Northern Norway; a case for the impact of perineural infiltration and post-
operative PSA-doubling time. BMC Urol 14: 49. Available: http://www.biomedcentral.com/1471-2490/
14/49. doi: 10.1186/1471-2490-14-49 PMID: 24929427
32. Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, et al. (2014) Prostate Stromal Cells Express the Progester-
one Receptor to Control Cancer Cell Mobility. PLoS One 9: e92714. Available: http://dx.doi.org/10.
1371/journal.pone.0092714. doi: 10.1371/journal.pone.0092714 PMID: 24664419
33. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, et al. (1998) Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nat Med 4: 844–847. doi: 10.1038/nm0798-
844 PMID: 9662379
34. Milanes-Yearsley M, Hammond MEH, Pajak TF, Cooper JS, Chang C, et al. (n.d.) Tissue Micro-Array:
A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study
Groups. Mod Pathol 15: 1366–1373. Available: http://dx.doi.org/10.1097/01.MP.0000036345.18944.
22. PMID: 12481019
Progesterone Receptor and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0116691 February 27, 2015 13 / 14
35. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, et al. (2007) The role of ex-
tranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene ex-
pression and the cell cycle. Mol Endocrinol 21: 359–375. doi: 10.1210/me.2006-0337 PMID: 17138644
36. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, et al. (1998) Activation of the Src/
p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:
2008–2018. doi: 10.1093/emboj/17.7.2008 PMID: 9524123
37. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activa-
tion of mitogen-activated protein kinases. Mol Endocrinol 19: 327–339. doi: 10.1210/me.2004-0306
PMID: 15486045
38. Hernández-Hernández OT, González-García TK, Camacho-Arroyo I (2012) Progesterone receptor
and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocyto-
ma cell lines. J Steroid BiochemMol Biol 132: 127–134. doi: 10.1016/j.jsbmb.2012.04.005 PMID:
22542550
39. Dohi O, Hatori M, Suzuki T, Ono K, Hosaka M, et al. (2008) Sex steroid receptors expression and hor-
mone-induced cell proliferation in human osteosarcoma. Cancer Sci 99: 518–523. doi: 10.1111/j.1349-
7006.2007.00673.x PMID: 18081879
40. Hanekamp EE, Gielen SCJP, Smid-Koopman E, Kühne LCM, de Ruiter PE, et al. (2003) Conse-
quences of loss of progesterone receptor expression in development of invasive endometrial cancer.
Clin Cancer Res 9: 4190–4199. PMID: 14519645
41. Check JH, Dix E, Cohen R, Check D, Wilson C (2010) Efficacy of the progesterone receptor antagonist
mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res
30: 623–628. PMID: 20332480
42. Check JH, Dix E, Wilson C, Check D (2010) Progesterone receptor antagonist therapy has therapeutic
potential even in cancer restricted to males as evidenced frommurine testicular and prostate cancer
studies. Anticancer Res 30: 4921–4923. PMID: 21187471
43. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM, Lin FF (1995) Growth inhibition of androgen-insensi-
tive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26:
194–204. PMID: 7716084
44. El Etreby MF, Liang Y, Johnson MH, Lewis RW (2000) Antitumor activity of mifepristone in the human
LNCaP, LNCaP-C4, and LNCaP-C4–2 prostate cancer models in nude mice. Prostate 42: 99–106.
doi: 10.1002/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I PMID: 10617866
45. GaoW, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev
105: 3352–3370. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
2096617&tool = pmcentrez&rendertype = abstract. PMID: 16159155
46. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, et al. (2007) Enhanced Paracrine FGF10
Expression Promotes Formation of Multifocal Prostate Adenocarcinoma and an Increase in Epithelial
Androgen Receptor. Cancer Cell 12: 572–585. doi: 10.1016/j.ccr.2007.11.002 PMID: 18068633
Progesterone Receptor and Prostate Cancer
PLOS ONE | DOI:10.1371/journal.pone.0116691 February 27, 2015 14 / 14
